Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Short-term Investments (2021 - 2025)

Kiniksa Pharmaceuticals International (KNSA) has disclosed Short-term Investments for 5 consecutive years, with $111.2 million as the latest value for Q1 2025.

  • For the quarter ending Q1 2025, Short-term Investments changed N/A year-over-year to $111.2 million, compared with a TTM value of $111.2 million through Mar 2025, changed N/A, and an annual FY2024 reading of $60.0 million, down 38.99% over the prior year.
  • Short-term Investments was $111.2 million for Q1 2025 at Kiniksa Pharmaceuticals International, up from $60.0 million in the prior quarter.
  • Across five years, Short-term Investments topped out at $126.4 million in Q3 2024 and bottomed at $210000.0 in Q1 2021.
  • Average Short-term Investments over 5 years is $69.6 million, with a median of $70.2 million recorded in 2022.
  • The sharpest move saw Short-term Investments surged 39068.1% in 2022, then plummeted 38.99% in 2024.
  • Year by year, Short-term Investments stood at $59.7 million in 2021, then increased by 13.66% to $67.9 million in 2022, then skyrocketed by 44.96% to $98.4 million in 2023, then plummeted by 38.99% to $60.0 million in 2024, then surged by 85.2% to $111.2 million in 2025.
  • Business Quant data shows Short-term Investments for KNSA at $111.2 million in Q1 2025, $60.0 million in Q4 2024, and $126.4 million in Q3 2024.